Summary
Medtronic plc reported net sales of $7.65 billion for the third quarter ended October 30, 2020, a slight decrease of 0.8% compared to the prior year quarter, largely due to the ongoing impacts of the COVID-19 pandemic. For the first six months of fiscal year 2021, net sales were $14.15 billion, down 6.9% year-over-year. Diluted earnings per share (EPS) for the quarter were $0.36, down significantly from $1.01 in the prior year, reflecting lower revenue and increased operating expenses. The company's financial performance continues to be influenced by the global pandemic, with a notable impact on procedural volumes across its various business segments. Despite the revenue decline, Medtronic demonstrated operational resilience. The company reported strong growth in certain areas, such as ventilators within the Minimally Invasive Therapies Group, driven by COVID-19 demand. However, other segments like Cardiac & Vascular Group and Restorative Therapies Group experienced declines due to deferred procedures. The company has initiated restructuring programs, 'Enterprise Excellence' and 'Simplification,' aiming for future efficiencies and cost savings. Medtronic maintained a strong liquidity position, with substantial cash and investments, and continued to focus on strategic capital allocation.
Financial Highlights
54 data points| Revenue | $7.65B |
| Cost of Revenue | $2.71B |
| Gross Profit | $4.94B |
| SG&A Expenses | $2.60B |
| Operating Income | $930.00M |
| Interest Expense | $470.00M |
| Net Income | $489.00M |
| EPS (Basic) | $0.36 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 1.34B |
| Shares Outstanding (Diluted) | 1.35B |
Key Highlights
- 1Q3 FY2021 net sales of $7.65 billion, a slight decrease of 0.8% year-over-year, impacted by COVID-19.
- 2First six months FY2021 net sales decreased by 6.9% to $14.15 billion.
- 3Diluted EPS of $0.36 for Q3 FY2021, a significant decrease from $1.01 in Q3 FY2020.
- 4Minimally Invasive Therapies Group saw growth driven by increased demand for COVID-19 related diagnostics and therapies, especially ventilators.
- 5Cardiac & Vascular Group and Restorative Therapies Group experienced sales declines due to reduced procedural volumes from the pandemic.
- 6Company initiated 'Simplification' restructuring program to improve agility and accelerate decision-making, with estimated costs of $400-$450 million.
- 7Strong liquidity position maintained with $6.4 billion in cash and cash equivalents and $7.9 billion in investments as of October 30, 2020.